Adma Biologics (ADMA) Change in Receivables (2011 - 2025)

Adma Biologics has reported Change in Receivables for 13 years, with the latest figure at $20.8 million in Q4 2025.

• For the quarter ending Q4 2025, Change in Receivables rose 14820.57% year-over-year to $20.8 million; the trailing twelve-month figure through Dec 2025 stood at $108.4 million (up 380.25% YoY), and the FY2025 full-year result was $108.4 million, up 380.25% from the prior year.
• Change in Receivables for Q4 2025 stood at $20.8 million, down from $27.9 million in the prior quarter.
• The five-year high for Change in Receivables was $49.4 million in Q1 2025, with the low at -$19.5 million in Q2 2024.
• Historically, Change in Receivables has averaged $7.3 million across 5 years, with a median of $5.2 million in 2021.
• Annual changes were most pronounced in 2021 — Change in Receivables plunged 1654.71% — and 2025, when it jumped 14820.57%.
• Adma Biologics' Change in Receivables stood at $8.2 million in 2021, then sank by 165.95% to -$5.4 million in 2022, then advanced by 27.78% to -$3.9 million in 2023, then soared by 96.38% to -$141000.0 in 2024, then jumped by 14820.57% to $20.8 million in 2025.
• The last three Change in Receivables figures came in at $20.8 million (Q4 2025), $27.9 million (Q3 2025), and $10.3 million (Q2 2025), per Business Quant data.